Close X
Attorney Spotlight

How did Sylvia Yi's previous work at the Department of Homeland Security prepare her for working with government contractors at Bass, Berry & Sims? Find out more>


Close X


Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

FCPA: 2016 Year in Review & 2017 Enforcement Predictions

A review of trends and developments in FCPA as well as a look ahead into what to expect for 2017. This report aims at providing corporate leaders and companies with the knowledge they need to comply with the FCPA and avoid litigation in 2017.

Read now

David Cox


(615) 742-6299 TEL
(615) 742-2864 FAX

David Cox


(615) 742-6299 TEL
(615) 742-2864 FAX
(615) 742-6299 TEL
(615) 742-2864 FAX

David Cox advises owners, executives and boards of emerging and growth companies in key corporate events, such as capital formation, private equity transactions, acquisitions and change in control transactions. David has advised on more than 400 transactions for private and public companies throughout the United States, including pioneers in their industry such as American HomePatient, Berlitz, Central Parking, ClinTrials and Pharmerica.

His representation covers a broad range of healthcare sectors, with particularly deep experience advising laboratory testing and life sciences, medical distribution and health software companies. A substantial portion of his representation also involves clients in financial services and financial technology and software. He also has advised clients in numerous other industries including retail services, logistics and distribution, technology and energy.

David's practice includes:

  • Mergers & Acquisitions – Advising clients on M&A transactions, including auction processes and representing both private equity and strategic buyers and sellers. Typically, his focus is on middle market transactions up to $1 billion.
  • Private Equity – Counseling private equity backed companies, with a particular focus on navigating the interplay between private equity/venture capital investors and portfolio company executive teams.
  • Board and Executive Advisory – Representing board of directors, special committees and individual executives of both public and private companies, including special situations such as going private transactions, special committee representation, audit committee investigations and takeover transactions.
  • Special Healthcare M&A Counsel- Providing specialized healthcare M&A support to private equity firms, coordinating with national and international transaction counsel, utilizing an approach designed to provide the client and its other advisors with seamless access to deep healthcare industry knowledge and experience.

Prior to joining Bass, Berry & Sims, David was a shareholder and executive committee member at Harwell Howard Hyne Gabbert & Manner, P.C.


Nashville Bar Association

Tennessee Bar Association

Texas Bar Association 

American Bar Association

American Health Lawyers Association (AHLA)


View More

Representative Experience

View More

Additional Experience

Additional representative experience (prior to joining Bass, Berry & Sims PLC)

  • Sale of laboratory software company to private equity sponsor
  • Acquisition by leading PE sponsored onsite clinic operator of an onsite/near site clinic operator
  • Healthcare counsel for acquisition of health software provider of automation to contract therapy market
  • Management representation in rollover in a PE firm to PE firm sale of a national distribution company
  • Sale of national financial services print and remit and software company by PE firm
  • Acquisition of solar energy field monitoring company by strategic solar buyer
  • Formation and funding of specialty lending company
  • Venture capital funding for business focused on alternative revenue opportunities for hospital systems
  • Sale of southwestern pathology laboratory company to strategic buyer
  • Auction process for sale of public medical device company
  • Special counsel on sale of national durable medical equipment supplier by PE firm
  • Healthcare counsel on acquisition of long-term care operations by strategic buyer
  • Sale of western toxicology laboratory company to PE consortium
  • Auction process for acquisition of hospital-based clinical laboratory company
  • Auction process for sale of specialty pipe manufacturer for energy and water projects
  • Capital formation for dental service organization
  • Refinancing transaction for national specialty medical distribution company
  • Healthcare counsel in auction process for acquisition of national occupational health screening and testing company
  • Healthcare counsel for acquisition of healthcare software company focused on 340B Program compliance

Past Events

View More


Martindale-Hubbell — AV Preeminent® Peer Review Rated

Chambers USA – Corporate/M&A (2005-2016)

Best Lawyers in America® – Corporate Governance Law; Corporate Law; Mergers & Acquisitions Law; Securities / Capital Markets Law (2005-2017)


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.